Adoptive t-cell immunotherapy in digestive tract malignancies: current challenges and future perspectives

T cells are at the forefront of the tumor immune surveillance. They are able to recognize tumor antigens, derived from intracellularly degraded proteins, that are loaded onto cell surface major histocompatibility complex (MHC) molecules through a unique, clone-specific receptor named T cell receptor (TCR). The TCR complex comprises highly polymorphic single α- and β-glycoprotein chains (1-5% of TCRs harbor γ and δ chains) that contain variable and constant regions, and non-polymorphic signaling chains named CD3 γ, δ, ε and ζ.

Source: Cancer Treatment Reviews - September 4, 2021 Category: Cancer & Oncology Authors: Barbara Mandriani, Eleonora Pelle', Gaetano Pezzicoli, Jonathan Strosberg, Daniel Abate-Daga, Attilio Guarini, Mauro Cives, Camillo Porta Source Type: research